HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court

This brief reviews the case now before the Supreme Court, Louisiana v. FDA, and provides an overview of the other pending litigation involving mifepristone, and the mounting tension between states seeking to protect abortion and the states banning the provision of abortion.

By KFF Health News · May 6, 2026 · via KFF Health News
Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court

Image: KFF Health News

This is an aggregated industry headline. Read the full story at KFF Health News

Tags
policyformat:headlineheadlineKFF Health News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
STAT+: More political interference at the FDA?
PolicySTAT News ↗
A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newslet…
May 7, 2026
Touting $529B in savings over 10 years, White House looks to expand MFN deals with pharma
PolicyFiercePharma ↗
Following a series of “most favored nation” pricing deals with 17 large pharma companies, the Trump administra…
May 7, 2026
Status of State Medicaid Expansion Decisions
PolicyKFF Health News ↗
This page displays an interactive map of the current status of state decisions on the Affordable Care Act's Me…
May 6, 2026